Adipocyte JAK2 mediates aging-associated metabolic liver disease and progression to hepatocellular carcinoma
preprint
OA: closed
Abstract
ABSTRACT Non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) are liver manifestations of the metabolic syndrome and can progress to hepatocellular carcinoma (HCC). Loss of Growth Hormone (GH) signaling is reported to predispose to NAFLD and NASH through direct actions on the liver. Here, we report that aged mice lacking hepatocyte Jak2 (JAK2L), an obligate transducer of Growth Hormone (GH) signaling, spontaneously develop the full spectrum of phenotypes found in patients with metabolic liver disease, beginning with insulin resistance and lipodystrophy and manifesting as NAFLD, NASH and even HCC, independent of dietary intervention. Remarkably, insulin resistance, metabolic liver disease, and carcinogenesis are prevented in JAK2L mice via concomitant deletion of adipocyte Jak2 (JAK2LA). Further, we demonstrate that GH increases hepatic lipid burden but does so indirectly via signaling through adipocyte JAK2. Collectively, these data establish adipocytes as the mediator of GH-induced metabolic liver disease and carcinogenesis. In addition, we report a new spontaneous model of NAFLD, NASH, and HCC that recapitulates the natural sequelae of human insulin resistance-associated disease progression. The work presented here suggests a attention be paid towards inhibition of adipocyte GH signaling as a therapeutic target of metabolic liver disease.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
References (59)
- doi:10.1038/nrgastro.2017.109 via crossref
- doi:10.1053/j.gastro.2018.08.024 via crossref
- doi:10.4103/jcar.jcar_9_16 via crossref
- doi:10.1016/j.drudis.2017.06.007 via crossref
- doi:10.3390/nu9101072 via crossref
- doi:10.1016/s0002-9343(99)00271-5 via crossref
- doi:10.2337/diabetes.50.8.1844 via crossref
- doi:10.1210/jc.2014-4464 via crossref
- doi:10.1530/joe-16-0513 via crossref
- doi:10.1016/j.cmet.2007.12.009 via crossref
- doi:10.2337/dbi16-0010 via crossref
- doi:10.1042/cs20070217 via crossref
- doi:10.1016/j.gde.2018.02.002 via crossref
- doi:10.2337/db10-0224 via crossref
- doi:10.1210/jc.2008-0079 via crossref
- doi:10.1210/en.2012-1849 via crossref
- doi:10.2337/diab.22.5.388 via crossref
- doi:10.1210/jc.2010-0493 via crossref
- doi:10.1172/jci.insight.91001 via crossref
- doi:10.2337/db17-0524 via crossref
- doi:10.1126/scitranslmed.3001845 via crossref
- doi:10.1016/j.ghir.2015.08.002 via crossref
- doi:10.1016/j.tem.2016.02.005 via crossref
- doi:10.3390/ijms18071447 via crossref
- doi:10.2337/db15-0370 via crossref
- doi:10.1172/jci42894 via crossref
- doi:10.1210/me.2013-1110 via crossref
- doi:10.2337/diacare.27.9.2204 via crossref
- doi:10.1016/j.cell.2012.03.017 via crossref
- doi:10.7314/apjcp.2015.16.11.4769 via crossref
- doi:10.1177/000313481007601119 via crossref
- doi:10.3390/nu5051544 via crossref
- doi:10.1016/j.cmet.2007.12.009 via crossref
- doi:10.1016/j.cmet.2018.08.020 via crossref
- doi:10.1073/pnas.1423952112 via crossref
- doi:10.1172/jci200523621 via crossref
- doi:10.1186/s12944-016-0194-7 via crossref
- doi:10.1210/en.2015-1866 via crossref
- doi:10.1530/joe-13-0477 via crossref
- doi:10.1016/j.molmet.2016.05.005 via crossref
- doi:10.1016/s1097-2765(00)00010-1 via crossref
- doi:10.1016/j.molmet.2016.04.001 via crossref
- doi:10.1001/jama.300.5.509 via crossref
- doi:10.1210/jc.87.2.942 via crossref
- doi:10.1210/en.2018-00669 via crossref
- doi:10.1002/hep.25900 via crossref
- doi:10.1038/srep34719 via crossref
- doi:10.1074/jbc.m116.752519 via crossref
- doi:10.1530/eje-18-0255 via crossref
- doi:10.1016/j.ghir.2015.08.004 via crossref
- doi:10.18632/oncotarget.18038 via crossref
- doi:10.1007/164_2016_45 via crossref
- doi:10.3389/fcell.2017.00035 via crossref
- doi:10.1194/jlr.m800393-jlr200 via crossref
- doi:10.1210/endo-120-5-1806 via crossref
- doi:10.1038/nature03043 via crossref
- doi:10.1002/gene.20063 via crossref
- doi:10.2337/diacare.26.8.2426 via crossref
- doi:10.1055/s-0032-1306421 via crossref
Source provenance
- crossref
- last seen: 2026-06-19T06:35:12.332781+00:00
- europepmc
- last seen: 2026-05-19T01:45:01.086888+00:00
- unpaywall
- last seen: 2026-08-03T06:41:53.707437+00:00